Indivior (NASDAQ:INDV) Insider Sells $764,628.04 in Stock

Indivior PLC (NASDAQ:INDV) insider Christian Heidbreder sold 18,586 shares of Indivior stock in a transaction dated Friday, July 10th. The shares were sold at an average price of $41.14, for a total value of $764,628.04. Following the completion of the transaction, the insider directly owned 209,337 shares of the company’s stock, valued at $8,612,124.18. This represents a 8.15% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Indivior Stock Up 1.7%

Shares of NASDAQ:INDV opened at $40.93 on Thursday. Indivior PLC has a 12 month low of $15.00 and a 12 month high of $42.81. The company’s 50-day moving average price is $38.61 and its two-hundred day moving average price is $35.11. The firm has a market cap of $4.99 billion, a P/E ratio of 20.99 and a beta of 0.86.

Indivior (NASDAQ:INDV) last posted its quarterly earnings data on Tuesday, March 31st. The company reported $0.96 earnings per share for the quarter. Indivior had a net margin of 19.44% and a negative return on equity of 219.26%. The firm had revenue of $317.00 million during the quarter. As a group, equities analysts predict that Indivior PLC will post 4.05 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on INDV. Weiss Ratings cut shares of Indivior from a “hold (c+)” rating to a “hold (c)” rating in a research report on Thursday, July 9th. Barclays assumed coverage on Indivior in a research report on Thursday, June 18th. They issued an “overweight” rating and a $46.00 price objective on the stock. Finally, Zacks Research cut Indivior from a “strong-buy” rating to a “hold” rating in a research note on Monday, June 29th. Six investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $40.29.

Institutional Trading of Indivior

Hedge funds have recently modified their holdings of the company. Caitong International Asset Management Co. Ltd raised its holdings in Indivior by 72.7% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,093 shares of the company’s stock worth $39,000 after purchasing an additional 460 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al grew its holdings in shares of Indivior by 3.4% in the 4th quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 21,200 shares of the company’s stock valued at $761,000 after buying an additional 700 shares during the period. Blue Trust Inc. increased its position in shares of Indivior by 17.8% in the 4th quarter. Blue Trust Inc. now owns 4,859 shares of the company’s stock valued at $176,000 after buying an additional 733 shares in the last quarter. Harbor Capital Advisors Inc. increased its position in shares of Indivior by 309.9% in the 4th quarter. Harbor Capital Advisors Inc. now owns 1,033 shares of the company’s stock valued at $37,000 after buying an additional 781 shares in the last quarter. Finally, Salomon & Ludwin LLC acquired a new stake in Indivior during the 4th quarter worth $30,000. 60.33% of the stock is currently owned by institutional investors and hedge funds.

About Indivior

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.